Carl Zeiss Meditec
- Ludwin Monz, President and CEO
- Michael Kaschke, Chairman of the Board
Carl Zeiss Meditec AG is a global medical technology company in the field. It manufactures instruments for eye examination, surgical microscopes, medical laser and intraocular lenses. Products include complete solutions for the most common and important diseases of ophthalmology.
The company was created in 2002 from the merger of Carl Zeiss Ophthalmic Systems AG and Asclepion -Meditec AG and is about 65 % owned by the Carl Zeiss Group. The remaining shares of companies listed in the Nasdaq Carl Zeiss Meditec AG are in free float.
On 21 October 2004 announced Carl Zeiss Meditec the acquisition of the " Laser Diagnostic Technologies, Inc." (LDT ) from San Diego (USA ), which was formally completed in December and strengthened in the field of glaucoma diagnosis.
Between 2004 and 2006, Carl Zeiss Meditec took over and after one hundred per cent share of the French Intraokularlinsenhersteller IOLTECH SA in La Rochelle, which was renamed Carl Zeiss Meditec SAS later. In October 2007, including the eye surgery specialist Acri.Tec GmbH from Hennig village was purchased.
On 1 June 2011 the Acri.Tec GmbH, surgical microscopes manufacturer Carl Zeiss Surgical GmbH and Carl Zeiss Meditec Systems GmbH and Carl Zeiss Medical Software GmbH were - all four wholly-owned subsidiaries of Carl Zeiss Meditec AG - merged with the parent company.
In 2014, the Company acquired CZ Aaren Scientific Inc., a manufacturer of intraocular lenses in the United States.
Group Structure and Business
The business of Carl Zeiss Meditec AG is divided organizationally into three Strategic Business Units ( SBUs ). In the field of ophthalmology, the Ophthalmic Systems SBU laser and diagnostic systems and the SBU offer Surgical Ophthalmology especially intraocular lenses (IOL ) and the associated consumables. The Microsurgery SBU provides surgical microscopes particular forth for use in ENT surgery and neurosurgery; she is also active in the field of intraoperative radiotherapy.
In addition to the German sites Jena, Oberkochen, Hennig village, Berlin and Munich, Carl Zeiss Meditec AG is represented with its consolidated subsidiaries in foreign locations. Carl Zeiss Meditec AG currently has, inter alia, the following wholly-owned subsidiaries ( as of September 30, 2013)
- Carl Zeiss Meditec Inc., Dublin, United States
- Carl Zeiss Meditec Co. Ltd.. , Tokyo, Japan
- Carl Zeiss Meditec Iberia SA, Tres Cantos, Spain
- Carl Zeiss Meditec Asset Management Management mbH, Jena, Germany Atlantic SAS, Le Pecq, France Hyaltech Ltd.. , Livingston, United Kingdom
- Carl Zeiss Meditec SAS, La Rochelle, France Carl Zeiss Meditec France SAS, Le Pecq, France
- Carl Zeiss Meditec mbH, Oberkochen
The Management Board of Carl Zeiss Meditec AG consists of three members:
- Ludwin Monz; CEO
- Christian Müller; Finance and Controlling, Investor Relations, Law and Taxes
- Thomas Simmerer; Sales and service.
The co-determined by the Drittelbeteiligungsgesetz Supervisory Board includes in addition to two employee representatives, the following four shareholder representatives:
- Michael Kaschke, Chairman, also CEO of Carl Zeiss AG
- Markus Guthoff, Vice Chairman
- Thomas Spitzenpfeil, also Member of the Executive Board of Carl Zeiss AG ( CFO)
- Wolfgang Reim.